{"entity":{"id":"blinatumomab-frontline-consolidation","kind":"pairing","name":"Blinatumomab added to frontline chemotherapy","aka":[],"tldr":"Interleaving an immunotherapy with standard chemotherapy cycles improves survival in adults and children with newly diagnosed ALL.","summary":"Adding blinatumomab, a CD19-directed bispecific T-cell engager, to frontline chemotherapy cycles is a combination pairing that improves survival in both adults and children with newly diagnosed B-cell acute lymphoblastic leukaemia. Chemotherapy reduces the bulk of disease and the immunosuppressive burden, after which blinatumomab engages the patient's recovering T cells against residual CD19-positive blasts. Two phase 3 trials, ECOG-ACRIN E1910 in adults who were already in MRD-negative remission and Children's Oncology Group AALL1731 in children with standard-risk disease, were both stopped early because of benefit. Blinatumomab is now a standard part of consolidation regardless of MRD status, and the linked papers describe both trials.","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT02003222: ECOG-ACRIN E1910","url":"https://clinicaltrials.gov/study/NCT02003222"},{"label":"ClinicalTrials.gov NCT03914625: COG AALL1731","url":"https://clinicaltrials.gov/study/NCT03914625"}],"tags":[],"related":[],"cancers":["all-leukemia","all-paediatric-standard-risk"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":["blinatumomab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["e1910","aall1731"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"a":"blinatumomab","b":"cytarabine-7-3","rationale":"Chemotherapy reduces bulk and immunosuppressive burden; blinatumomab then engages the patient's recovering T cells against residual CD19+ blasts.","evidence":"Two positive phase 3 trials.","pairingType":"combination"},"route":"/pairings/blinatumomab-frontline-consolidation/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"},{"id":"cytarabine-7-3","kind":"drug","name":"Cytarabine + anthracycline ('7+3')","route":"/drugs/cytarabine-7-3/"}],"trial":[{"id":"aall1731","kind":"trial","name":"COG AALL1731","route":"/trials/aall1731/"},{"id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","route":"/trials/e1910/"}],"paper":[{"id":"paper-aall1731-blinatumomab-children-nejm-2025","kind":"paper","name":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","route":"/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/"},{"id":"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","kind":"paper","name":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","route":"/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/"}]}}